---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-018818"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:32:00.217027+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte reports Q1 net loss $60.5M; VAX-24 Phase 2 meets endpoints in adults 65+

## Summary
- Net loss of $60.5M in Q1 2023 vs $39.0M in Q1 2022; R&D expenses $58.1M, up from $31.7M.
- Cash, cash equivalents and investments $949.9M as of March 31, 2023, excluding $545.1M net proceeds from recent public offering.
- Positive Phase 2 data for VAX-24 in adults 65+: at 2.2mcg dose, met OPA non-inferiority for 18/20 common serotypes vs PCV20 and superiority for all 4 unique serotypes.
- Dosed first participants in VAX-24 infant Phase 2 study; topline data expected by 2025.
- Completed $575M follow-on public offering in April 2023; VAX-31 IND submission expected H2 2023, Phase 1/2 data in 2024.

## SEC filing metadata
- accession: 0000950170-23-018818
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000095017023018818/0000950170-23-018818-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000095017023018818/pcvx-20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-018818
- JSON: https://secwatch.observer/filing/0000950170-23-018818.json
- Plain text: https://secwatch.observer/filing/0000950170-23-018818.txt

## Key facts
- Earnings Releases
  Vaxcyte, Inc. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 8, 2023, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000095017023018818/0000950170-23-018818-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.